Mostrar el registro sencillo del ítem

dc.contributor.authorGomez Rial, Jose 
dc.contributor.authorCurras-Tuala, M J
dc.contributor.authorTalavero González, Cristina 
dc.contributor.authorRodríguez-Tenreiro, C
dc.contributor.authorVilanova Trillo, Lucía
dc.contributor.authorGómez Carballa, Alberto
dc.contributor.authorRivero Calle, Irene 
dc.contributor.authorJusticia Grande, Antonio José 
dc.contributor.authorPardo Seco, Jacobo José
dc.contributor.authorRedondo Collazo, Lorenzo 
dc.contributor.authorSalas, A.
dc.contributor.authorMartinón Torres, Federico 
dc.date.accessioned2017-09-05T10:17:54Z
dc.date.available2017-09-05T10:17:54Z
dc.date.issued2017
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/?term=28558652es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/9462
dc.description.abstractThe IFI27 interferon gene expression has been found to be largely increased in rotavirus (RV)-infected patients. IFI27 gene encodes for a protein of unknown function, very recently linked to epidermal proliferation and related to the epidermal growth factor (EGF) protein. The EGF is a low-molecular-weight polypeptide that is mainly produced by submandibular and parotid glands, and it plays an important physiological role in the maintenance of oro-esophageal and gastric tissue integrity. Our aim was to determine salivary EGF levels in RV-infected patients in order to establish its potential relationship with IFI27 increased expression and EGF-mediated mucosal protection in RV infection. We conducted a prospective comparative study using saliva samples from 27 infants infected with RV (sampled at recruitment during hospital admission and at convalescence, i.e. at least 3 months after recovery) and from 36 healthy control children. Median (SD) EGF salivary concentration was 777 (529) pg/ml in RV-infected group at acute phase and 356 (242) pg/m at convalescence, while it was 337 (119) pg/ml in the healthy control group. A significant association was found between EGF levels and hospitalization length of stay (P-value = 0.022; r(2) = -0.63). The salivary levels of EGF are significantly increased during the acute phase of natural RV infection, and relate to length of hospitalization. Further assessment of this non-invasive biomarker in RV disease is warranted.es
dc.description.sponsorshipInstituto de Salud Carlos IIIes
dc.description.sponsorshipXunta de Galicia. Consellería de Sanidadees
dc.language.isoenges
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshRotavirus*
dc.subject.meshEpidermal Growth Factor*
dc.subject.meshSaliva*
dc.subject.meshConvalescence*
dc.titleSalivary epidermal growth factor correlates with hospitalization length in rotavirus infectiones
dc.typeArtigoes
dc.rights.holderLos autoreses
dc.identifier.doi10.1186/s12879-017-2463-0
dc.identifier.essn1471-2334
dc.identifier.pmid28558652
dc.issue.number1es
dc.journal.titleBMC Infectious Diseaseses
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostelaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Análise clínicoses
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Pediatríaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS)es
dc.page.initial370es
dc.relation.projectIDInstituto de Salud Carlos III/(Proyecto de Investigación en Salud, Acción Estratégica en Salud): project GePEM ISCIII/ PI16/01478/Cofinanciado FEDER) (A.S.)es
dc.relation.projectIDInstituto de Salud Carlos III/Rotanext ISCIII/PI13/02382 and ReSVinext ISCIII/PI16/01569/Cofinanciado FEDER (F.M.T.)es
dc.relation.projectIDConsellería de Sanidade, Xunta de Galicia/ (RHI07/2-intensificación actividad investigadora, PS09749 and 10PXIB918184PRes
dc.relation.projectIDFondo de Investigación Sanitaria (FIS; PI070069/PI1000540) del plan nacional de I + D + I y ‘ fondos FEDER ’ (F.M.T.es
dc.relation.projectID2016-PG071 Consolidación e Estructuración REDES 2016GI-1344 G3VIP (Grupo Gallego de Genética Vacunas Infecciones y Pediatría, ED341D R2016/021)(A.S. and F.M.es
dc.relation.projectIDInstituto de Salud Carlos III/ (Intensificación de la actividad investigadora 2007 – 2012, PI16/01569)es
dc.relation.publisherversionhttps://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-017-2463-0es
dc.rights.accessRightsopenAccesses
dc.subject.decsconvalecencia*
dc.subject.decsRotavirus*
dc.subject.decssaliva*
dc.subject.decsfactor de crecimiento epidérmico*
dc.subject.keywordBiomarkerses
dc.subject.keywordBiomarcadoreses
dc.subject.keywordEGFes
dc.subject.keywordIFI27es
dc.subject.keywordRotavirus infectiones
dc.subject.keywordInfección por rotaviruses
dc.subject.keywordTiempo de hospitalizaciónes
dc.subject.keywordTempo de hospitalizaciónes
dc.typefidesArtigo Científico (inclue Orixinal, Orixinal breve, Revisión Sistemática e Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number17es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional